CANN GLOBAL LIMITED ACN 124 873 507

Sholom Feldman Director 21 February 2019

TWELFTH SUPPLEMENTARY PROSPECTUS

1. IMPORTANT INFORMATION

This is a twelfth supplementary prospectus (Twelfth Supplementary Prospectus) which is intended to be read with the prospectus dated 27 September 2018, the initial supplementary prospectus dated 17 October 2018 (First Supplementary Prospectus), the second supplementary prospectus dated 31 October 2018 (Second Supplementary Prospectus), the third supplementary prospectus dated 7 November 2018 (Third Supplementary Prospectus), the fourth supplementary prospectus dated 14 November 2018 (Fourth Supplementary Prospectus), the fifth supplementary prospectus dated 28 November 2018 (Fifth Supplementary **Prospectus**), the sixth supplementary prospectus dated 7 December 2018 (Sixth Supplementary Prospectus), the seventh supplementary prospectus dated 14 December 2018 (Seventh Supplementary Prospectus), the eighth supplementary prospectus dated 21 December 2018 (Eighth Supplementary Prospectus), the ninth supplementary prospectus dated 24 December 2018 (Ninth Supplementary Prospectus), the tenth supplementary prospectus dated 25 January 2019 (Tenth **Supplementary Prospectus**) and the eleventh supplementary prospectus dated 8 February 2019 (Eleventh Supplementary Prospectus) (the initial prospectus, the First Supplementary Prospectus, the Second Supplementary Prospectus, the Third Supplementary Prospectus, the Fourth Supplementary Prospectus, the Fifth Prospectus, Sixth Supplementary Prospectus, Supplementary Eighth Supplementary Prospectus, Supplementary Prospectus, Supplementary Prospectus, Tenth Supplementary Prospectus and Eleventh Supplementary Prospectus collectively referred to in this document as the **Prospectus**) issued by Cann Global Limited (ACN 124 873 507) (Company).

This Twelfth Supplementary Prospectus is dated 21 February 2019 and was lodged with the ASIC and ASX on that date. The ASIC, ASX and their officers take no responsibility for the contents of this Tenth Supplementary Prospectus.

This Twelfth Supplementary Prospectus should be read together with the Prospectus. Other than as set out below, all details in relation to the Prospectus remain unchanged. Terms and abbreviations defined in the Prospectus have the same meaning in this Twelfth Supplementary Prospectus. If there is a conflict between the Prospectus and this Twelfth Supplementary Prospectus, this Twelfth Supplementary Prospectus will prevail.

This Twelfth Supplementary Prospectus will be issued with the Prospectus as an electronic prospectus and may be accessed on the Company's website at https://www.canngloballimited.com. This is an important document and should be read in its entirety. If you do not understand it, you should consult your professional advisers without delay.

This Twelfth Supplementary Prospectus is intended to be read with the prospectus dated 27 September 2018, the initial supplementary prospectus dated 17 October 2018, the second supplementary prospectus dated 31 October 2018, the third supplementary prospectus dated 7 November 2018, the fourth supplementary prospectus dated 14 November 2018, the fifth supplementary prospectus dated 28 November 2018, the sixth supplementary prospectus dated 7 December 2018, the seventh supplementary prospectus dated 14 December 2018, the eighth supplementary prospectus dated 21 December 2018, the ninth supplementary prospectus dated 24 December 2018, the tenth supplementary prospectus dated 25 January 2019 and the eleventh supplementary prospectus dated 8 February 2019 issued by Cann Global Limited (ACN 124 873 507).

2. EXTENSION OF OFFERS

As announced on 8 February 2019, the Company has entered into an agreement with BioHealth Pharmaceuticals Pty Ltd and restructured its transaction with Medcan Australia Pty Ltd. Following consultation with the ASX, the Company is required to prepare further documentation, re-seek shareholder approval for the transactions and issue an updated prospectus. These documents are currently being prepared. The Company currently expects the relisting process to take approximately 6 weeks primarily to allow for the calling of the extraordinary general meeting to obtain the required new shareholder approval of the transactions. The Company will issue a further update confirming the new expected timetable as soon as possible.

As a result, the Company has decided to extend the Offers to 25 March 2019.

This date is indicative only and may change without notice. The Company reserves the right to close the Offers early or extend the closing dates of the Offers without prior notice. The Company also reserves the right not to proceed with the Offers at any time before the issue of Securities to Applicants.

3. DIRECTORS' AUTHORISATION

This Twelfth Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with Section 720 of the Corporations Act, each Director has consented to the lodgement of this Twelfth Supplementary Prospectus with the ASIC.

Sholom Feldman
Managing Director and Company Secretary
For and on behalf of
CANN GLOBAL LIMITED

This Twelfth Supplementary Prospectus is intended to be read with the prospectus dated 27 September 2018, the initial supplementary prospectus dated 17 October 2018, the second supplementary prospectus dated 31 October 2018, the third supplementary prospectus dated 7 November 2018, the fourth supplementary prospectus dated 14 November 2018, the fifth supplementary prospectus dated 28 November 2018, the sixth supplementary prospectus dated 7 December 2018, the seventh supplementary prospectus dated 14 December 2018, the eighth supplementary prospectus dated 21 December 2018, the ninth supplementary prospectus dated 24 December 2018, the tenth supplementary prospectus dated 25 January 2019 and the eleventh supplementary prospectus dated 8 February 2019 issued by Cann Global Limited (ACN 124 873 507).